QUOTE AND NEWS
StreetInsider.com  Aug 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TREXIMET+Rights+Acquired+by+Pernix+Therapeutics+%28PTX%29+%28POZN%29+%28GSK%29/9769580.html for the full story.
SeekingAlpha  Aug 11  Comment 
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) Q2 2014 Results Conference Call August 11, 2014; 10:00 a.m. ET Executives Doug Drysdale - Chairman, President & Chief Executive Officer Sanjay Patel - Chief Financial Officer Tracy...
StreetInsider.com  Aug 4  Comment 
* Pike Corporation (NYSE: PIKE) announced today that it has signed a definitive merger agreement under which investment firm Court Square Capital Partners in partnership with J. Eric Pike, the Company's Chairman and Chief Executive Officer, will...
StreetInsider.com  Jun 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Pernix+Therapeutics+%28PTX%29+Names+New+CFO/9604950.html for the full story.
StreetInsider.com  May 15  Comment 
52-Week High: Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX) $6.40. Pernix Therapeutics moving higher again Thursday after announcing Wednesday that it signed an agreement with GlaxoSmithKline to acquire the U.S rights to Treximet (sumatriptan...
StreetInsider.com  May 15  Comment 
UPGRADES Cowen upgrades Plug Power (Nasdaq: PLUG) from Market Perform to Outperform, but moves its price target from $7.50 to $6. Click Here for more color. Needham & Company lifts Pernix Therapeutics (Nasdaq: PTX) from Buy to Strong Buy while...
TheStreet.com  May 15  Comment 
NEW YORK (TheStreet) -- Shares of Pernix Therapeutics Holdings are up 7.33% to $6.00 after Needham upgraded the specialty pharmaceutical company to "strong buy" from "buy," saying its acquisition of Treximet was a "game changer." Needham said...
StreetInsider.com  May 14  Comment 
52-Week High: Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX) $6.10. Pernix Therapeutics ramping today after it signed an agreement with GlaxoSmithKline to acquire the U.S rights to Treximet (sumatriptan / naproxen sodium) for the acute...
StreetInsider.com  May 14  Comment 
Summer Infant, Inc. (Nasdaq: SUMR) 48.8% HIGHER; reported Q1 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $50.8 million versus the consensus estimate of $45.22 million. Pernix Therapeutics...
TheStreet.com  May 14  Comment 
NEW YORK (TheStreet) -- Pernix Therapeutics  soared more than 35% to a one-year high of $6.10 on Wednesday after the pharmaceutical company announced it would acquire the U.S rights to Treximet in an agreement with GlaxoSmithKline . Treximet...





 



References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki